echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Leukemia: Efficacy and Safety of Guadecitabine in Patients with Peripheral T-Cell Lymphoma

    Leukemia: Efficacy and Safety of Guadecitabine in Patients with Peripheral T-Cell Lymphoma

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy with an extremely poor prognosis when it relapses


    Guadecitabine, a decitabine analog, has shown good efficacy in MDS patients


    This study is a single-center Phase II clinical trial recruiting patients 18 years of age and older with an ECOG performance status of ≤3, histologically diagnosed, treatment-naïve, or relapsed/refractory PTCL, treated with Treatment with citabine (60 mg/m2) on days 1-5/28 until disease progression




    The overall response rate was 40%, including 10% complete response The overall response rate was 40%, including 10% complete response



    RHOAG17V mutation is associated with prolonged progression-free survival

    In conclusion, Guadecitabine demonstrated acceptable overall response rates and toxicity profiles in patients with peripheral T-cell lymphoma ; decitabine analogs may be promising candidates for future combined targeting of histone methyltransferases.


    Guadecitabine demonstrated acceptable overall response rate and toxicity profile in patients with peripheral T-cell lymphoma Guadecitabine demonstrated acceptable overall response rate and toxicity profile in patients with peripheral T-cell lymphoma Overall response rate and toxicity profile

     

    Original source:

    Original Source: Original Source:

    Wong Jonathan, Gruber Emily, Maher Belinda et al.


    Wong Jonathan, Gruber Emily, Maher Belinda et al.
    Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
    [J] .
    Leukemia, 2022, https://doi.
    org/10.
    1038/s41375- 022-01571-8

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.